A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity

References

• Ogden CL, Fryar CD, Martin CB, et al. Trends in obesity prevalence by race and Hispanic origin - 1999-2000 to 2017–2018. JAMA. 2020;324(12):1208–1210. doi:10.1001/JAMA.2020.14590
   PubMed Web of Science ®Google Scholar
• Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2). doi:10.1542/PEDS.2022-060640
   Web of Science ®Google Scholar
• Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: the obesity society 2018 position statement. Obesity. 2019;27(1):7–9. doi:10.1002/OBY.22378
   PubMed Web of Science ®Google Scholar
• De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5). doi:10.1542/PEDS.2009-2107C
   Google Scholar
• Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA. 2018;319(16):1723–1725. doi:10.1001/JAMA.2018.3060
   PubMed Web of Science ®Google Scholar
• Raman V, Gupta A, Ashraf AP, et al. Pharmacologic weight management in the era of adolescent obesity. J Clin Endocrinol Metab. 2022;107(10):2716–2728. doi:10.1210/CLINEM/DGAC418
   PubMed Web of Science ®Google Scholar
• Czepiel KS, Perez NP, Campoverde Reyes KJ, Sabharwal S, Stanford FC. Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol. 2020;11:290. doi:10.3389/fendo.2020.00290
   PubMed Web of Science ®Google Scholar
• Kühnen P, Biebermann H, Wiegand S. Pharmacotherapy in childhood obesity. Horm Res Paediatr. 2022;95(2):177–192. doi:10.1159/000518432
   PubMed Web of Science ®Google Scholar
• Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738–741. doi:10.1007/S00431-004-1534-6
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–2883. doi:10.1001/JAMA.293.23.2873
   PubMed Web of Science ®Google Scholar
• Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes. 2017;41(1):90–93. doi:10.1038/IJO.2016.185
   Web of Science ®Google Scholar
• Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–2128. doi:10.1056/NEJMOA1916038
   PubMed Web of Science ®Google Scholar
• Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22(4):480–491. doi:10.1111/DOM.13910
   PubMed Web of Science ®Google Scholar
• Dhillon S. Phentermine/topiramate: pediatric first approval. Paediatr Drugs. 2022;24(6):715–720. doi:10.1007/S40272-022-00532-Z
   PubMed Web of Science ®Google Scholar
• Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–2257. doi:10.1056/NEJMOA2208601
   PubMed Web of Science ®Google Scholar
• Johnson VR, Washington TB, Chhabria S, et al. Food as medicine for obesity treatment and management. Clin Ther. 2022;44(5):671–681. doi:10.1016/J.CLINTHERA.2022.05.001
   PubMed Web of Science ®Google Scholar
• Nicolucci A, Maffeis C. The adolescent with obesity: what perspectives for treatment? Ital J Pediatr. 2022;48(1). doi:10.1186/S13052-022-01205-W
   PubMed Web of Science ®Google Scholar
• Dabas A, Seth A. Prevention and management of childhood obesity. Indian J Pediatr. 2018;85(7):546–553. doi:10.1007/S12098-018-2636-X
   PubMed Web of Science ®Google Scholar
• Singhal V, Sella AC, Malhotra S. Pharmacotherapy in pediatric obesity: current evidence and landscape. Curr Opin Endocrinol Diabetes Obes. 2021;28(1):55–63. doi:10.1097/MED.0000000000000587
   PubMedGoogle Scholar
• Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105–1112. doi:10.1007/S11695-020-04987-2
   PubMed Web of Science ®Google Scholar
• Borzutzky C, King E, Fox CK, et al. Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: data from the POWER Work Group. Pediatr Obes. 2021;16(1). doi:10.1111/IJPO.12701
   PubMed Web of Science ®Google Scholar
• Garrett SD, Cupp MJ. The fenfluramine/phentermine combination for weight loss. Nurse Pract. 1997;22(8):166, 168, 170.
   PubMedGoogle Scholar
• Stunkard AJ. Anorectic agents lower a body weight set point. Life Sci. 1982;30(24):2043–2055. doi:10.1016/0024-3205(82)90445-3
   PubMed Web of Science ®Google Scholar
• Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation. 1999;99(1):156–161. doi:10.1161/01.CIR.99.1.156
   PubMed Web of Science ®Google Scholar
• Torretta LK. Dexfenfluramine, fenfluramine, and phentermine for the treatment of morbid obesity. J Am Acad Nurse Pract. 1997;9(8):389–399. doi:10.1111/j.1745-7599.1997.tb01261.x
   PubMedGoogle Scholar
• Howlin D. Fenfluramine and phentermine. Ann Intern Med. 2001;135(9):840–841. doi:10.7326/0003-4819-135-9-200111060-00018
   PubMed Web of Science ®Google Scholar
• Sehnert KW. Development of phentermine, an appetite-control drug. Clin Med. 1963;70:400–403.
   Google Scholar
• Craig DDH. Chlorphentermine. Br Med J. 1963;2(5367):1269. doi:10.1136/bmj.2.5367.1269
   PubMedGoogle Scholar
• Seaton DA, Rose K, Duncan LJP. A comparison of the appetite suppressing properties of dexamphetamine and phentermine. Scott Med J. 1964;9(11):482–485. doi:10.1177/003693306400901104
   PubMedGoogle Scholar
• Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65(10):1391–1418. doi:10.2165/00003495-200565100-00006
   PubMed Web of Science ®Google Scholar
• Lim S, Rogers LK, Tessler O, Mundinger GS, Rogers C, Lau FH. Phentermine: a systematic review for plastic and reconstructive surgeons. Ann Plast Surg. 2018;81(4):508. doi:10.1097/SAP.0000000000001478
   Web of Science ®Google Scholar
• Papasava M, Singer G, Papasava CL. Phentermine self-administration in naive free-feeding and food-deprived rats: a dose response study. Psychopharmacology. 1985;85(4):410–413. doi:10.1007/BF00429655
   PubMed Web of Science ®Google Scholar
• Becker BA. Pharmacologic activity of phentermine (phenyl-t-butylamine). Toxicol Appl Pharmacol. 1961;3(2):256–259. doi:10.1016/S0041-008X(61)80010-0
   PubMed Web of Science ®Google Scholar
• Go RE, Hwang KA, Kim SH, et al. Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model. Lab Anim Res. 2014;30(2):73. doi:10.5625/LAR.2014.30.2.73
   PubMedGoogle Scholar
• Klein S, Romijn JA. Obesity. In: Williams Textbook of Endocrinology. Elsevier; 2016:1633–1659. doi:10.1016/B978-0-323-29738-7.00036-8
   Google Scholar
• Kiortsis DN. A review of the metabolic effects of controlled-release phentermine/topiramate. Hormones. 2013;12(4):507–516. doi:10.14310/HORM.2002.1438
   PubMedGoogle Scholar
• Jo HS, Wang SM, Kim JJ. Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report. Clin Psychopharmacol Neurosci. 2019;17(1):130–133. doi:10.9758/cpn.2019.17.1.130
   PubMed Web of Science ®Google Scholar
• Murali S. Knowledge gaps in long-term phentermine use: making the case for maintenance. Obesity. 2019;27(8):1219. doi:10.1002/oby.22516
   PubMed Web of Science ®Google Scholar
• Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity. 2021;29(6):985–994. doi:10.1002/OBY.23152
   PubMed Web of Science ®Google Scholar
• Hung YM, Chang JC. Weight-reducing regimen associated with polymorphic ventricular tachycardia. Am J Emerg Med. 2006;24(6):714–716. doi:10.1016/j.ajem.2006.02.004
   PubMed Web of Science ®Google Scholar
• Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France (Regulation). Prescrire Int. 2012;21(130):209.
   PubMedGoogle Scholar
• Khalil NY, AlRabiah HK, Rashoud SS AL, Bari A, Wani TA. Topiramate: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2019;44:333–378. doi:10.1016/BS.PODRM.2018.11.005
   PubMedGoogle Scholar
• Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes. 2014;38(2):292–298. doi:10.1038/IJO.2013.74
   Web of Science ®Google Scholar
• Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27(4):591–602. doi:10.1002/oby.22430
   PubMed Web of Science ®Google Scholar
• Ali Ibrahim AI, Mendoza B, Stanford FC, Malhotra S. Real-world experience of the efficacy and safety of phentermine use in adolescents: a case series. Child Obes. 2022. doi:10.1089/CHI.2022.0147
   PubMed Web of Science ®Google Scholar
• Lorber J. Obesity in childhood. A controlled trial of anorectic drugs. Arch Dis Child. 1966;41(217):309–312. doi:10.1136/ADC.41.217.309
   PubMed Web of Science ®Google Scholar
• Ryder JR, Kelly AS, Freedman DS. Metrics matter: toward consensus reporting of BMI and weight-related outcomes in pediatric obesity clinical trials. Obesity. 2022;30(3):571–572. doi:10.1002/OBY.23346
   PubMed Web of Science ®Google Scholar
• Rauh JL, Lipp R. Chlorphentermine as an anorexigenic agent in adolescent obesity. Report of its efficacy in a double-blind study of 30 teen-agers. Clin Pediatr. 1968;7(3):138–140. doi:10.1177/000992286800700305
   PubMed Web of Science ®Google Scholar
• Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr. 2015;54(1):19–24. doi:10.1177/0009922814542481
   PubMed Web of Science ®Google Scholar
• Fox CK, Kaizer AM, Rudser KD, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity. 2016;24(12):2553–2561. doi:10.1002/OBY.21633
   PubMed Web of Science ®Google Scholar
• Consoli A, Çabal Berthoumieu S, Raffin M, et al. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl Psychiatry. 2019;9(1). doi:10.1038/S41398-019-0597-0
   PubMedGoogle Scholar
• Berman C, Naguib M, Hegedus E, Vidmar AP, Topiramate for Weight Management in Children With Severe Obesity. Child Obes. 2023;19(4):219–225. doi:10.1089/chi.2022.0062
   PubMed Web of Science ®Google Scholar
• Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evidence. 2022;1(6). doi:10.1056/EVIDOA2200014
   PubMedGoogle Scholar
• Boxill GC, M BEN, Hillyard IW, Warren MR. The cardiovascular and extravascular smooth muscle actions of chlorphentermine hydrochloride (p-chloro-alpha, alpha-dimethylphenethylamine)-a new anorexigenic agent. J Pharmacol Exp Ther. 1962;137:198–205.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. Obesity. 2022;30(4):802–840. doi:10.1002/oby.23371
   PubMed Web of Science ®Google Scholar
• Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359–375. doi:10.1080/00325481.2022.2051366
   PubMed Web of Science ®Google Scholar
• Glauser TA. Topiramate. Epilepsia. 1999;40(SUPPL. 5):s71–s80. doi:10.1111/J.1528-1157.1999.TB00922.X
   PubMed Web of Science ®Google Scholar
• Shapiro M, Reid A, Olsen B, Taasan M, McNamara J, Nguyen M. Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: a medical record review. Int J Psychiatry Med. 2016;51(1):56–68. doi:10.1177/0091217415621266
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338–e347. doi:10.1111/J.1467-789X.2010.00846.X
   PubMed Web of Science ®Google Scholar
• Rawls SM, Thomas T, Adeola M, et al. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav. 2009;93(4):363–367. doi:10.1016/J.PBB.2009.05.005
   PubMed Web of Science ®Google Scholar
• Turenius CI, Htut MM, Prodon DA, et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res. 2009;1262:16–24. doi:10.1016/J.BRAINRES.2009.01.016
   PubMed Web of Science ®Google Scholar
• Turenius CI, Charles JR, Tsai DH, et al. The tuberal lateral hypothalamus is a major target for GABAA--but not GABAB-mediated control of food intake. Brain Res. 2009;1283:65–72. doi:10.1016/J.BRAINRES.2009.05.064
   PubMed Web of Science ®Google Scholar
• Miner P, Borkuhova Y, Shimonova L, Khaimov A, Bodnar RJ. GABA-A and GABA-B receptors mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions. Brain Res. 2010;1355:86–96. doi:10.1016/J.BRAINRES.2010.07.109
   PubMed Web of Science ®Google Scholar
• Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol. 2012;209:433–466. doi:10.1007/978-3-642-24716-3_20/FIGURES/1_20
   Google Scholar
• Liang Y, She P, Wang X, Demarest K. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism. 2006;55(10):1411–1419. doi:10.1016/J.METABOL.2006.06.013
   PubMed Web of Science ®Google Scholar
• Sweeting AN, Tabet E, Caterson ID, Markovic TP. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes Metab Syndr Obes. 2014;7:35–44. doi:10.2147/DMSO.S38979
   PubMedGoogle Scholar
• Tennis P, Chan KA, Curkendall SM, et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res a Clin Mol Teratol. 2015;103(4):269–275. doi:10.1002/BDRA.23357
   PubMed Web of Science ®Google Scholar
• Rafi SK, Goering JP, Olm-Shipman AJ, et al. Anti-epileptic drug topiramate upregulates TGFβ1 and SOX9 expression in primary embryonic palatal mesenchyme cells: implications for teratogenicity. PLoS One. 2021;16(2):e0246989. doi:10.1371/JOURNAL.PONE.0246989
   PubMed Web of Science ®Google Scholar
• Green MW, Seeger JD, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. Headache. 2012;52(7):1070–1084. doi:10.1111/j.1526-4610.2012.02190.x
   PubMed Web of Science ®Google Scholar
• Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405.e1–405.e7. doi:10.1016/j.ajog.2012.07.008
   PubMed Web of Science ®Google Scholar
• Mines D, Tennis P, Curkendall SM, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23(10):1017–1025. doi:10.1002/pds.3612
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, De Saint-Martin A, Mancini J, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003;53(3):225–232. doi:10.1016/S0920-1211(03)00028-7
   PubMed Web of Science ®Google Scholar
• Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(10):1304–1312. doi:10.1111/J.1526-4610.2005.00262.X
   PubMed Web of Science ®Google Scholar
• Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry. 2005;4(1). doi:10.1186/1744-859X-4-5
   PubMedGoogle Scholar
• Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777–1801. doi:10.1586/ERC.10.125
   PubMedGoogle Scholar
• Johnson DB, Quick J. Topiramate and phentermine. StatPearls; 2023. Available from: https://pubmed.ncbi.nlm.nih.gov/29489234/. Accessed March 27, 2023.
   Google Scholar
• Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340–349. doi:10.1345/APH.1R501
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity. 2013;21(11):2163–2171. doi:10.1002/OBY.20584
   PubMed Web of Science ®Google Scholar
• Kartal Ö, Kartal AT. Phentermine plus topiramate for weight reduction: more tolerable and effective? Clin Pediatr. 2015;54(3):302. doi:10.1177/0009922814566935
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):141. doi:10.1056/NEJM199708283370901
   PubMed Web of Science ®Google Scholar
• Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab. 2003;88(6):2462–2469. doi:10.1210/JC.2003-030151
   PubMed Web of Science ®Google Scholar
• Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32(6):1178–1188. doi:10.1097/HJH.0000000000000145
   PubMed Web of Science ®Google Scholar
• Griffen L, Anchors M. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking “phen-fen”. Arch Intern Med. 1998;158(1):102. doi:10.1001/ARCHINTE.158.1.102
   PubMedGoogle Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet. 2011;377(9774):1341–1352. doi:10.1016/S0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308. doi:10.3945/AJCN.111.024927
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330–342. doi:10.1038/OBY.2011.330
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399(10321):259–269. doi:10.1016/S0140-6736(21)01640-8
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86. doi:10.1001/JAMA.2013.281361
   PubMed Web of Science ®Google Scholar
• Li J, Reaven NL, Funk SE, McGaughey K, Neovius M. 4-year cost trajectories in real-world patients matched to the metabolic profiles of trial subjects before/after treatment with phentermine-topiramate. Drugs Real World Outcomes. 2015;2(2):143–151. doi:10.1007/S40801-015-0021-X
   PubMedGoogle Scholar
• Gómez Lumbreras A, Tan MS, Villa-Zapata L, Ilham S, Earl JC, Malone DC. Cost-effectiveness analysis of five anti-obesity medications from a US payer’s perspective. Nutr Metab Cardiovasc Dis. 2023;33(6):1268–1276. doi:10.1016/J.NUMECD.2023.03.012
   PubMed Web of Science ®Google Scholar
• Fox CK, Kelly AS. Pharmacotherapy for severe obesity in children. Clin Pediatr. 2015;54(13):1302. doi:10.1177/0009922815580407
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637–646. doi:10.1056/NEJMOA1903822
   PubMed Web of Science ®Google Scholar